Share This Page
Suppliers and packagers for gilenya
✉ Email this page to a colleague
gilenya
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527 | NDA | Novartis Pharmaceuticals Corporation | 0078-0607-15 | 30 CAPSULE in 1 BOTTLE (0078-0607-15) | 2010-09-21 |
| Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527 | NDA | Novartis Pharmaceuticals Corporation | 0078-0965-89 | 7 CAPSULE in 1 CARTON (0078-0965-89) | 2010-09-21 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for gilenya
GILENYA (fingolimod) Suppliers: API, Finished Dose, and Key Contract Manufacturers
Executive summary: GILENYA (fingolimod) is supplied commercially by Novartis as the finished drug product. For business planning across the supply chain, the practical supplier universe centers on (i) Novartis-led ownership/control of the branded supply and (ii) specialized contract manufacturing for drug substance (API) and oral capsule drug product typically disclosed via GMP/contractor records, regulatory filings, and procurement documentation. This landscape is licensing- and geography-specific and shifts with plant qualification, lifecycle transfers, and validated manufacturing sites.
What’s protected and who controls supply: The supplier question for GILENYA is inseparable from exclusivity and lifecycle stewardship because Novartis controls branded supply continuity and quality systems tied to validated commercial manufacturing sites.
Who supplies GILENYA (fingolimod) in the US and EU?
Direct branded supply:
- Novartis is the marketed source of GILENYA in major markets, with distribution through regional Novartis pharma networks.
Regulatory-facing reality:
- The label and regulatory product dossiers identify the marketing authorization holder/MAH (EU) and applicant (US) and link those to listed manufacturing sites for the capsule and the API in quality sections. In practice, those sites determine the “real” supplier pool for procurement, transfer, and tech transfer timelines.
Operational distinction to track:
- “Supplier” can mean commercial vendor for finished goods vs manufacturer of the API vs contract packager for capsules. Contract roles for branded products frequently change at site transfer or scale-up, while the MAH stays fixed.
Which companies manufacture the fingolimod API (drug substance) for GILENYA?
API sourcing pattern for branded small molecules:
- For oral small-molecule drugs, API is typically manufactured under GMP at one or more qualified plants, with the marketing authorization holder controlling the commercial supply chain and the quality dossier linkage.
Commercial implications for procurement and litigation readiness:
- API site changes usually require regulatory notifications/updates and may trigger CMC comparability work, especially if polymorph, impurity profile, or scale change occurs. This drives which vendors can realistically be qualified without rerunning substantial validation.
Practical supplier universe for due diligence:
- Only manufacturers whose sites are listed in regulatory CMC/quality sections for the marketed product and those that have passed qualification by the MAH are “supplier candidates” for near-term supply continuity.
(Note: a precise, named list of API contractors for GILENYA requires exact site-level information from regulatory listings and quality dossier documents; the topic prompt does not include those identifiers.)
Which contract manufacturers produce the GILENYA capsules (finished drug product)?
Finished dose supply chain components:
- Capsule filling and finishing
- Blending, granulation, tableting equivalent steps are typically not applicable (capsule form)
- Encapsulation and packaging validation
- Stability program maintenance
- Serialisation where required
How to interpret “supplier” in procurement systems:
- In pharma procurement, vendors are often listed at three levels:
- MAH/regional distributor (commercial supplier)
- Finished dose manufacturer (GMP site for capsules)
- Packaging supplier (secondary packaging lines, bottle/blister operations)
Lifecycle driver:
- GILENYA supply continuity depends on validated site capacity. For branded products, contract manufacturing expansion is used to de-risk bottlenecks, but only after comparability and regulatory update pathways are satisfied.
(Named facility-level contract manufacturers require the specific regulatory manufacturing site list for the marketed strength and dosage form.)
What are the dosing forms and strengths that affect GILENYA supply?
GILENYA is supplied as oral capsules. The supplier qualification and sourcing can differ by:
- Strength (dose-specific granule and filling operations)
- Package configuration (bottles vs blister, if applicable in a geography)
- Lot release site and QC release location
Procurement impact:
- Even when the API supplier remains constant, capsule filling and packaging contractors may differ by plant or campaign.
How do manufacturing site changes affect GILENYA regulatory filings?
Typical CMC triggers for branded oral solids:
- API process changes (affecting impurity profile)
- Solvent system or crystallization parameters
- Scale changes requiring comparability
- Finished dose manufacturing line changes
- Equipment changes (mixers, granulators, capsule filling lines)
- Site transfers (new GMP facility)
Regulatory mechanics for risk management:
- Site changes are usually accompanied by regulatory updates and validation reports to maintain the approved quality specifications and dissolution/assay/impurity criteria.
What is the supplier risk profile for GILENYA (fingolimod)?
Key risk vectors:
- Single- or dual-site dependence for API or finished capsules
- Complex impurity controls for small-molecule APIs
- Serialization and packaging line capacity
- Cold chain is not typical for this class; the risk is mostly capacity and QC, not temperature logistics
- Regulatory change management burden during transfers
Business takeaway:
- Supplier diversification is possible, but only through qualified site addition and dossier linkage. For a branded product with long-held approval history, supplier transitions are slower than new generic entrants.
How strong are exclusivity and patent control factors for GILENYA supply?
Supplier landscapes are shaped by exclusivity and regulatory pathways because they determine:
- Incentives for generic API availability in commercial supply
- Timing of “authorized” supply shifts
- Whether firms pursue biosimilar-style substitution (not applicable here) or generic equivalence
What this means in practice:
- GILENYA is a branded immunomodulator with active competitive and generic pressures. However, branded supply continuity remains under MAH control unless a lawful launch or authorized generic arrangement changes the market structure.
Which distributors supply GILENYA to pharmacies and hospitals?
Distribution layers:
- Regional Novartis distribution arms (typical for branded products)
- Pharmacy wholesaler channels (US) that buy from the MAH or authorized distributor
- Hospital pharmacy procurement contracts
Procurement note:
- Contracting for branded oncology/neurology immunomodulators typically follows existing distributor panels, with tenders updated by local payer and formulary decisions.
(Named distributors vary by country and wholesaler contracts; a fixed list requires the specific jurisdictional supply chain.)
How does GILENYA compare with other multiple-sclerosis oral injectables for supplier structure?
For multiple sclerosis (MS) oral therapies, supplier structures usually share features:
- MAH controls CMC and site qualification
- One or two qualified API manufacturers
- One or more capsule/solid-dose plants
Differences show up in:
- Complexity of API synthesis
- Number of commercial strengths
- Packaging configurations by market
Strategic comparison:
- GILENYA’s supply is managed as a regulated branded oral solid where contract manufacturing is used but heavily constrained by dossier linkage.
Key Takeaways
- Branded supply is controlled by Novartis as the MAH/marketing source of GILENYA in major markets.
- “Supplier” breaks into layers: finished dose manufacturer(s), API manufacturer(s), packaging/secondary packaging, and regional distributors.
- Site transfers and supplier changes are gated by CMC comparability, impurity profile control, and dossier linkage.
- Named supplier lists at API and capsule levels require site-level regulatory manufacturing data for the specific GILENYA strength and geography, which is not included in the prompt.
FAQs
1) Are API manufacturers for GILENYA the same worldwide?
Not necessarily. Qualified API sites can differ by region and lifecycle transfer schedules, but the MAH controls which sites are approved for commercial supply.
2) Can a contract manufacturer produce GILENYA capsules for any MS market?
Only after regulatory qualification in that jurisdiction for the relevant strength/package configuration.
3) What typically constrains switching GILENYA suppliers?
CMC comparability, validated impurity profiles, and capsule filling/packaging validation tied to quality specifications.
4) Is the GILENYA supply chain exposed to temperature-sensitive logistics?
GILENYA is an oral capsule; the dominant risks are capacity/QC and compliance rather than cold-chain distribution.
5) Do generic launches materially change who supplies fingolimod capsules?
They change market procurement and volumes, but branded supply continuity remains MAH-controlled unless authorized supply arrangements or lawful launches shift commercial sourcing.
References (APA)
- FDA Orange Book. (n.d.). GILENYA (fingolimod) drug products. U.S. Food and Drug Administration.
- EMA. (n.d.). GILENYA (fingolimod) EPAR and product information. European Medicines Agency.
More… ↓
